AxoGen Inc の最大収益セグメントは Peripheral Nerve Regeneration and Repair で、最新の利益発表における収益は 187,338,000 です。地域別に見ると、United States が AxoGen Inc の主要市場であり、収益は 187,338,000 です。
AxoGen Incは収益を上げていますか?
いいえ、最新の財務諸表によると、AxoGen Incの純損失は$0です。
AxoGen Incに負債はありますか?
いいえ、AxoGen Incの負債は0です。
AxoGen Incの発行済株式数は何株ですか?
AxoGen Incの総発行済株式数は0株です。
主要データ
前終値
$49.15
始値
$49.4
当日レンジ
$48.79 - $50.66
52週レンジ
$13.5 - $50.19
取引高
962.8K
平均取引高
1.2M
配当利回り
--
1株当たり利益(TTM)
-0.68
時価総額
$2.6B
AXGNとは何ですか?
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 622 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.